INCIDENCE AND PROGNOSIS OF EPSTEIN-BARR VIRUS-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN VERY ELDERLY PATIENTS (AGED OVER 80 YEARS)
(Abstract release date: 05/19/16)
EHA Library. Tomikawa T. 06/09/16; 134595; PB1695
Dr. Tatsuki Tomikawa
Contributions
Contributions
Abstract
Abstract: PB1695
Type: Publication Only
Background
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly-described lymphoproliferative disorder (LPD) as a provisional entity in the 2008 WHO classification. The definition is a clonal B-cell proliferation associated with EBV, age at diagnosis over 50 years, and no secondary immune deficiencies. The prognosis is reportedly significantly inferior compared with EBV-negative DLBCL.
Aims
The aim of this study was to clarify the incidence of EBV infection and its related clinical features in very elderly patients with DLBCL.
Methods
We retrospectively analyzed 190 DLBCL patients diagnosed in our institute from January 2008 to December 2013. Diagnoses were immunohistochemically confirmed and the in situ hybridization detection technique for EBV-encoded small RNAs (EBER) was performed in all cases. EBV results were compared with clinical and immunochemical data according to age.
Results
The median age was 70.0 (22.7-97.1) years, and the median follow-up duration was 33.6 (0.2-96.5) months. The average EBER positivity was 4.6% in all patients. The mean EBV positivity of tumor samples in age groups were: 20-49 years (n=25), 0%; 50-59 years (n=32), 3.6%; 60-69 years, (n=38), 3.8%; 70-79 years (n=61), 8.9%; and over 80 years (n=34), 3.4% (1/34). The 5-year overall survival (OS) of all 190 patients was 58.2%, and that of EBV-positive patients (n=8) was 62.5%; the difference was not significant.
Conclusion
The reported incidence of EBV-positive DLBCL among patients of Asian and Latin American origin ranges from 9 to 15%, and the incidence of EBV-associated LPD increases with advancing age (Castillo JJ, et al. Oncologist 2011; 16: 87-96). Only 4.6% of the current DLBCL patients were EBER-positive; the reported peak (8.9%) was in the 70-79 years group, whereas the peak in that group in our cohort was only 3.4%. The immunophenotypic analysis results were similar in each age group, suggesting the patient population of this study was not deviated. In contrast to previous reports, the prognosis for EBV-positive and -negative DLBCL was similar. In conclusion, the characteristics of the EBV-positive DLBCL of the elderly identified in this study differ in several ways from that previously reported, and may be a new subtype of B-cell lymphoma; further studies to examine this possibility are warranted.
Session topic: E-poster
Keyword(s): DLBCL, EBV, Elderly, Prognosis
Type: Publication Only
Background
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly-described lymphoproliferative disorder (LPD) as a provisional entity in the 2008 WHO classification. The definition is a clonal B-cell proliferation associated with EBV, age at diagnosis over 50 years, and no secondary immune deficiencies. The prognosis is reportedly significantly inferior compared with EBV-negative DLBCL.
Aims
The aim of this study was to clarify the incidence of EBV infection and its related clinical features in very elderly patients with DLBCL.
Methods
We retrospectively analyzed 190 DLBCL patients diagnosed in our institute from January 2008 to December 2013. Diagnoses were immunohistochemically confirmed and the in situ hybridization detection technique for EBV-encoded small RNAs (EBER) was performed in all cases. EBV results were compared with clinical and immunochemical data according to age.
Results
The median age was 70.0 (22.7-97.1) years, and the median follow-up duration was 33.6 (0.2-96.5) months. The average EBER positivity was 4.6% in all patients. The mean EBV positivity of tumor samples in age groups were: 20-49 years (n=25), 0%; 50-59 years (n=32), 3.6%; 60-69 years, (n=38), 3.8%; 70-79 years (n=61), 8.9%; and over 80 years (n=34), 3.4% (1/34). The 5-year overall survival (OS) of all 190 patients was 58.2%, and that of EBV-positive patients (n=8) was 62.5%; the difference was not significant.
Conclusion
The reported incidence of EBV-positive DLBCL among patients of Asian and Latin American origin ranges from 9 to 15%, and the incidence of EBV-associated LPD increases with advancing age (Castillo JJ, et al. Oncologist 2011; 16: 87-96). Only 4.6% of the current DLBCL patients were EBER-positive; the reported peak (8.9%) was in the 70-79 years group, whereas the peak in that group in our cohort was only 3.4%. The immunophenotypic analysis results were similar in each age group, suggesting the patient population of this study was not deviated. In contrast to previous reports, the prognosis for EBV-positive and -negative DLBCL was similar. In conclusion, the characteristics of the EBV-positive DLBCL of the elderly identified in this study differ in several ways from that previously reported, and may be a new subtype of B-cell lymphoma; further studies to examine this possibility are warranted.
Session topic: E-poster
Keyword(s): DLBCL, EBV, Elderly, Prognosis
Abstract: PB1695
Type: Publication Only
Background
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly-described lymphoproliferative disorder (LPD) as a provisional entity in the 2008 WHO classification. The definition is a clonal B-cell proliferation associated with EBV, age at diagnosis over 50 years, and no secondary immune deficiencies. The prognosis is reportedly significantly inferior compared with EBV-negative DLBCL.
Aims
The aim of this study was to clarify the incidence of EBV infection and its related clinical features in very elderly patients with DLBCL.
Methods
We retrospectively analyzed 190 DLBCL patients diagnosed in our institute from January 2008 to December 2013. Diagnoses were immunohistochemically confirmed and the in situ hybridization detection technique for EBV-encoded small RNAs (EBER) was performed in all cases. EBV results were compared with clinical and immunochemical data according to age.
Results
The median age was 70.0 (22.7-97.1) years, and the median follow-up duration was 33.6 (0.2-96.5) months. The average EBER positivity was 4.6% in all patients. The mean EBV positivity of tumor samples in age groups were: 20-49 years (n=25), 0%; 50-59 years (n=32), 3.6%; 60-69 years, (n=38), 3.8%; 70-79 years (n=61), 8.9%; and over 80 years (n=34), 3.4% (1/34). The 5-year overall survival (OS) of all 190 patients was 58.2%, and that of EBV-positive patients (n=8) was 62.5%; the difference was not significant.
Conclusion
The reported incidence of EBV-positive DLBCL among patients of Asian and Latin American origin ranges from 9 to 15%, and the incidence of EBV-associated LPD increases with advancing age (Castillo JJ, et al. Oncologist 2011; 16: 87-96). Only 4.6% of the current DLBCL patients were EBER-positive; the reported peak (8.9%) was in the 70-79 years group, whereas the peak in that group in our cohort was only 3.4%. The immunophenotypic analysis results were similar in each age group, suggesting the patient population of this study was not deviated. In contrast to previous reports, the prognosis for EBV-positive and -negative DLBCL was similar. In conclusion, the characteristics of the EBV-positive DLBCL of the elderly identified in this study differ in several ways from that previously reported, and may be a new subtype of B-cell lymphoma; further studies to examine this possibility are warranted.
Session topic: E-poster
Keyword(s): DLBCL, EBV, Elderly, Prognosis
Type: Publication Only
Background
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is a newly-described lymphoproliferative disorder (LPD) as a provisional entity in the 2008 WHO classification. The definition is a clonal B-cell proliferation associated with EBV, age at diagnosis over 50 years, and no secondary immune deficiencies. The prognosis is reportedly significantly inferior compared with EBV-negative DLBCL.
Aims
The aim of this study was to clarify the incidence of EBV infection and its related clinical features in very elderly patients with DLBCL.
Methods
We retrospectively analyzed 190 DLBCL patients diagnosed in our institute from January 2008 to December 2013. Diagnoses were immunohistochemically confirmed and the in situ hybridization detection technique for EBV-encoded small RNAs (EBER) was performed in all cases. EBV results were compared with clinical and immunochemical data according to age.
Results
The median age was 70.0 (22.7-97.1) years, and the median follow-up duration was 33.6 (0.2-96.5) months. The average EBER positivity was 4.6% in all patients. The mean EBV positivity of tumor samples in age groups were: 20-49 years (n=25), 0%; 50-59 years (n=32), 3.6%; 60-69 years, (n=38), 3.8%; 70-79 years (n=61), 8.9%; and over 80 years (n=34), 3.4% (1/34). The 5-year overall survival (OS) of all 190 patients was 58.2%, and that of EBV-positive patients (n=8) was 62.5%; the difference was not significant.
Conclusion
The reported incidence of EBV-positive DLBCL among patients of Asian and Latin American origin ranges from 9 to 15%, and the incidence of EBV-associated LPD increases with advancing age (Castillo JJ, et al. Oncologist 2011; 16: 87-96). Only 4.6% of the current DLBCL patients were EBER-positive; the reported peak (8.9%) was in the 70-79 years group, whereas the peak in that group in our cohort was only 3.4%. The immunophenotypic analysis results were similar in each age group, suggesting the patient population of this study was not deviated. In contrast to previous reports, the prognosis for EBV-positive and -negative DLBCL was similar. In conclusion, the characteristics of the EBV-positive DLBCL of the elderly identified in this study differ in several ways from that previously reported, and may be a new subtype of B-cell lymphoma; further studies to examine this possibility are warranted.
Session topic: E-poster
Keyword(s): DLBCL, EBV, Elderly, Prognosis
{{ help_message }}
{{filter}}